BiochemistryJournal of Medicinal ChemistryPeer-reviewed
Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19
Yuto Unoh, Keiichiro Hirai, Shota Uehara…·Yuki Tachibana
This paper describes the discovery of S-892216, a potent SARS-CoV-2 3CLpro inhibitor with antiviral activity against multiple variants and low cross-resistance to existing drugs.
27 citationstop 1%